MPEROR-Preserved, the LOOP study, ablate-and-pace for AF, and salt substitute and stroke: John Mandrola, MD provides a first of two ESC reviews. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

1 – HFpEF

– EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough https://www.medscape.com/viewarticle/957405

– Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038

– Empagliflozin and Major Renal Outcomes in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMc2112411

– Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2022190

2 – AF Screening

– LOOP Trial Undercuts Value of Long-term Continuous ECG Screening for Atrial Fibrillation https://www.medscape.com/viewarticle/957473

– Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext

– Subclinical Atrial Fibrillation and the Risk of Stroke https://www.nejm.org/doi/full/10.1056/nejmoa1105575

3 – Ablate and Pace for AF and HF

– APAF-CRT: ‘Ablate and Pace’ Cuts Mortality in Narrow-QRS HF, Permanent AF https://www.medscape.com/viewarticle/957467

– A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS https://academic.oup.com/eurheartj/article/39/45/3999/5078460

– AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial https://doi.org/10.1093/eurheartj/ehab569

4 – Salt Substitute and Stroke

– Salt Substitute Shows Clear Reduction in Stroke, CV Events, and Death https://www.medscape.com/viewarticle/957472

– Effect of Salt Substitution on Cardiovascular Events and Death https://www.nejm.org/doi/full/10.1056/NEJMoa2105675

Features:

– Incremental, Not Monumental, Win for Empagliflozin in Heart Failure With Preserved Ejection Fraction https://www.medscape.com/viewarticle/957465

– Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context https://www.medscape.com/viewarticle/957388

– Lessons on AF Screening From the LOOP Study https://www.medscape.com/viewarticle/957512

– Ablate-and-Pace Delivers a Huge Win for Those Sick With AF https://www.medscape.com/viewarticle/958033

– Will the Positive Findings From the SSaSS Trial on Salt Substitution Silence the Salt Skeptics? https://www.medscape.com/viewarticle/957510

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

After one of Dr David Kerr’s patients attempted suicide, it made him think about the degree of suicidal ideation that may occur in cancer patients and how oncologists can better help.
https://wb.md/3kwa2s0

Dr David Johnson celebrates the arrival of much-needed recommendations on the indications and techniques for endoscopic tattooing in the colon.
https://wb.md/3zz64VY

To watch the entire series please click here: https://www.medscape.com/mtv/metastatic-breast-cancer-s01?&faf=1

About this Series

Hormone receptor–positive is the most common breast cancer, accounting for approximately 80% of all cases. Although metastatic HR+/HER2- breast cancer remains incurable, it is increasingly manageable. Expanded treatment options, including targeted agents used in combination with endocrine therapy, are extending the lives of women with metastatic breast cancer, and careful monitoring of biomarkers helps indicate when it is appropriate to change therapies. Increased emphasis on diet and exercise, psychosocial support, and symptom management—especially of bone metastases—contributes to an increased quality of life for women with metastatic disease.

Experts at Dana-Farber Cancer Institute discuss the ways in which treatment of HR+/HER2- metastatic breast cancer is evolving into an individualized approach, and how metastatic breast cancer patients are taking an active role as partners in the research of their disease.

Dr Anne Peters discusses blood glucose targets and continuous glucose monitoring in pregnant patients with type 1 diabetes.
https://www.medscape.com/viewarticle/946530